Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 12 2022 - 2:56PM
Edgar (US Regulatory)
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
|
OMB
APPROVAL |
OMB
Number: 3235-0058
Expires:
March 31, 2022
Estimated
average burden hours
per
response 2.50 |
|
SEC
FILE NUMBER
000-55413 |
|
CUSIP
NUMBER
15114L104 |
(Check
one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR
For
Period Ended: March 31, 2022
Transition
Report on Form 10-K
Transition
Report on Form 20-F
Transition
Report on Form 11-K
Transition
Report on Form 10-Q
Transition
Report on Form N-SAR
For
the Transition Period Ended: ___________________________________________________________
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information
contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
|
PART
I — REGISTRANT INFORMATION |
|
Cell
Source, Inc. |
Full
Name of Registrant |
|
|
Former
Name if Applicable |
|
57
West 57th Street, Suite 400 |
Address
of Principal Executive Office (Street and Number) |
|
New
York, New York 10019 |
City,
State and Zip Code |
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
☒ |
|
(a) |
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense |
|
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
(Attach
extra Sheets if Needed)
Cell
Source, Inc. (the “Registrant”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q
for the three months ended March 31, 2022 (the “Quarterly Report”) by the May 16, 2022 filing deadline applicable
to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures
in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly
Report. The Registrant anticipates that it will file the
Quarterly Report no later than the fifth calendar day following the prescribed filing date.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification |
Itamar
Shimrat |
(646) |
416-7896 |
(Name) |
(Area
Code) |
(Telephone
Number) |
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed ? If answer is no, identify report(s). Yes No |
|
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion thereof ? Yes No |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
Cell
Source, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
May 12, 2022 |
By:
|
/s/
Itamar Shimrat |
|
|
Itamar
Shimrat, Chief Executive Officer |
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
Cell Source (CE) (USOTC:CLCS)
Historical Stock Chart
From May 2024 to Jun 2024
Cell Source (CE) (USOTC:CLCS)
Historical Stock Chart
From Jun 2023 to Jun 2024